Acorda Therapeutics Inc
ACOR
Get informed when a big investor buys or sells
+ FollowMarket Cap$821.03K
Close$
$7.00
958.2% upside
Current Fair Value
958.2% upsideUndervalued by 958.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $821,028.00 |
|---|---|
| Enterprise Value | $187.67 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-203.59 |
| Beta | 1.46 |
| Outstanding Shares | 1,242,000 |
Return
| Return on Equity | 141.80% |
|---|---|
| Return on Assets | -322.92% |
| Return on Invested Capital | 16.75% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | -0.01 |
| Price to Sales | 0.01 |
| Price to Book Ratio | -0.0 |
| Enterprise Value to Revenue | 1.62 |
| Enterprise Value to EBIT | -7.87 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1.05 |
| Debt to Equity | -1.06 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Acorda Therapeutics Inc
CEO: Ron Cohen